JP2007535549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007535549A5 JP2007535549A5 JP2007510953A JP2007510953A JP2007535549A5 JP 2007535549 A5 JP2007535549 A5 JP 2007535549A5 JP 2007510953 A JP2007510953 A JP 2007510953A JP 2007510953 A JP2007510953 A JP 2007510953A JP 2007535549 A5 JP2007535549 A5 JP 2007535549A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- aryl
- heteroarylalkyl
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 73
- 125000000217 alkyl group Chemical group 0.000 claims 58
- 125000003118 aryl group Chemical group 0.000 claims 27
- 125000003710 aryl alkyl group Chemical group 0.000 claims 26
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 26
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- -1 Spiroalkyl Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 7
- 239000002830 appetite depressant Substances 0.000 claims 6
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 6
- 208000030814 Eating disease Diseases 0.000 claims 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 235000014632 disordered eating Nutrition 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 4
- 239000000883 anti-obesity agent Substances 0.000 claims 4
- 229940125710 antiobesity agent Drugs 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000005157 alkyl carboxy group Chemical group 0.000 claims 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 2
- 125000005012 alkyl thioether group Chemical group 0.000 claims 2
- 125000003435 aroyl group Chemical group 0.000 claims 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 125000005215 cycloalkylheteroaryl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000003106 haloaryl group Chemical group 0.000 claims 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims 2
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000012948 isocyanate Substances 0.000 claims 2
- 150000002513 isocyanates Chemical class 0.000 claims 2
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 claims 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 claims 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108010043412 neuropeptide Y-Y1 receptor Proteins 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229910052721 tungsten Inorganic materials 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 0 CC1=C*(*)C=*1 Chemical compound CC1=C*(*)C=*1 0.000 description 8
- SOXCUYKWCXNSJN-UHFFFAOYSA-N CC(C)Cc1ccccc1Cl Chemical compound CC(C)Cc1ccccc1Cl SOXCUYKWCXNSJN-UHFFFAOYSA-N 0.000 description 1
- RITUGMAIQCZEOG-UHFFFAOYSA-N CC(C)c1nc2ccccc2[nH]1 Chemical compound CC(C)c1nc2ccccc2[nH]1 RITUGMAIQCZEOG-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N CCC1CCCCC1 Chemical compound CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- CHLICZRVGGXEOD-UHFFFAOYSA-N Cc(cc1)ccc1OC Chemical compound Cc(cc1)ccc1OC CHLICZRVGGXEOD-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56684504P | 2004-04-30 | 2004-04-30 | |
| PCT/US2005/014518 WO2005111031A2 (en) | 2004-04-30 | 2005-04-28 | Neuropeptide receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007535549A JP2007535549A (ja) | 2007-12-06 |
| JP2007535549A5 true JP2007535549A5 (enExample) | 2008-05-15 |
Family
ID=35124538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007510953A Withdrawn JP2007535549A (ja) | 2004-04-30 | 2005-04-28 | 神経ペプチドレセプターモジュレーター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7459450B2 (enExample) |
| EP (1) | EP1747218A2 (enExample) |
| JP (1) | JP2007535549A (enExample) |
| CN (1) | CN1972937A (enExample) |
| CA (1) | CA2564751A1 (enExample) |
| MX (1) | MXPA06012504A (enExample) |
| WO (1) | WO2005111031A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080034436A (ko) * | 2005-07-21 | 2008-04-21 | 베타게논 에이비 | 암 치료에 사용되는 티아졸 유도체 및 유사체 |
| WO2007049532A1 (ja) * | 2005-10-25 | 2007-05-03 | Shionogi & Co., Ltd. | アミノジヒドロチアジン誘導体 |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| RU2476430C2 (ru) | 2007-04-24 | 2013-02-27 | Сионоги Энд Ко., Лтд. | Производные аминодигидротиазина, замещенные циклической группой |
| BRPI0915500A2 (pt) | 2008-06-13 | 2019-08-27 | Shionogi & Co | derivado heterocíclico contendo enxofre tendo atividade inibitória de beta secretase |
| EP2360155A4 (en) | 2008-10-22 | 2012-06-20 | Shionogi & Co | 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT |
| WO2010086613A1 (en) | 2009-01-30 | 2010-08-05 | Betagenon Ab | Compounds useful as inhibitors as ampk |
| BR112012013854A2 (pt) | 2009-12-11 | 2019-09-24 | Shionogi & Co | derivados de oxazina. |
| WO2012057247A1 (ja) | 2010-10-29 | 2012-05-03 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| EP2703399A4 (en) | 2011-04-26 | 2014-10-15 | Shionogi & Co | OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF |
| EP2869897A4 (en) | 2012-07-06 | 2016-09-28 | Univ Duke | ACTIVATION OF THE TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND IMPORTANT ROLE FOR TRPV4 IN ORGANIC INFLAMMATION AND JUCKREIZ |
| US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| WO2014127881A1 (de) | 2013-02-25 | 2014-08-28 | Merck Patent Gmbh | 2-amino-3,4-dihydrc-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren |
| WO2016028325A1 (en) * | 2014-08-22 | 2016-02-25 | Duke University | Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| WO2016043260A1 (ja) * | 2014-09-19 | 2016-03-24 | 塩野義製薬株式会社 | 環状グアニジンまたはアミジン化合物 |
| US11229628B2 (en) | 2015-01-09 | 2022-01-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| EP3439656A4 (en) | 2016-04-07 | 2020-03-11 | Duke University | DOUBLE SMALL MOLECULE INHIBITORS OF TRPV4 AND TRPA1 FOR DISINFECTION AND ANESTHESIA |
| WO2020113077A1 (en) | 2018-11-29 | 2020-06-04 | The Research Foundation For The State University Of New York | Compositions and methods for modular control of bioorthogonal ligation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO252896A0 (en) * | 1996-09-24 | 1996-10-17 | Fujisawa Pharmaceutical Co., Ltd. | Amidine derivatives |
| GB9825652D0 (en) * | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| WO2003009848A1 (en) * | 2001-07-20 | 2003-02-06 | Pfizer Products Inc. | Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses |
| CA2528438A1 (en) * | 2003-06-03 | 2005-01-06 | Novartis Ag | P-38 inhibitors |
-
2005
- 2005-04-28 EP EP05742268A patent/EP1747218A2/en not_active Withdrawn
- 2005-04-28 US US11/117,584 patent/US7459450B2/en not_active Expired - Fee Related
- 2005-04-28 CA CA002564751A patent/CA2564751A1/en not_active Abandoned
- 2005-04-28 CN CNA2005800210507A patent/CN1972937A/zh active Pending
- 2005-04-28 JP JP2007510953A patent/JP2007535549A/ja not_active Withdrawn
- 2005-04-28 WO PCT/US2005/014518 patent/WO2005111031A2/en not_active Ceased
- 2005-04-28 MX MXPA06012504A patent/MXPA06012504A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007535549A5 (enExample) | ||
| JP6528957B2 (ja) | Ｔｒｋ阻害化合物 | |
| JP5261575B2 (ja) | 化学化合物 | |
| US6387938B1 (en) | Benzimidazole derivatives | |
| ES2222363T3 (es) | Medicamento contra enfermedades viricas. | |
| ES2442907T3 (es) | Tiazolil dihidropirimidinas sustituidas con bromo-fenilo | |
| JP2012509903A5 (enExample) | ||
| JP2009533410A5 (enExample) | ||
| JP2011507878A5 (enExample) | ||
| JP2011502956A5 (enExample) | ||
| JP2009535357A (ja) | １１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤 | |
| JP2006508970A5 (enExample) | ||
| JP7627008B2 (ja) | ピロール化合物 | |
| JP2005532392A5 (enExample) | ||
| JP2011503081A5 (enExample) | ||
| JP2024515062A (ja) | 重水素化ｄｈｏｄｈ阻害剤 | |
| JP2007502817A5 (enExample) | ||
| RU2014100744A (ru) | Лечение респираторных нарушений с помощью trpa1 антагонистов | |
| JPH0725864A (ja) | 化学療法剤としての１，２，４−ジチアゾリウム塩類の使用 | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| JP2006500372A5 (enExample) | ||
| JP2004526721A5 (enExample) | ||
| JP2013532146A5 (enExample) | ||
| CN117321035A (zh) | 氘化的dhodh抑制剂 | |
| JP2009511422A5 (enExample) |